Last reviewed · How we verify

NCT04893837: MOBI-1

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

Completed Last updated 2 September 2025
What this trial tests

trial testing Standard care plus infrascans in Brain Injuries, Traumatic in 399 participants. Completed in 25 August 2025.

Timeline
18 April 2022
Primary endpoint
17 June 2025
25 August 2025

Quick facts

Lead sponsorUniversity of Alabama at Birmingham
StatusCompleted
Study typeOBSERVATIONAL
Enrollment399
Start date18 April 2022
Primary completion17 June 2025
Estimated completion25 August 2025
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Alabama at Birmingham

Who can join

15 and older, any sex, with Brain Injuries, Traumatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Injuries, Traumatic

Currently open trials in the same condition.

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04893837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing